XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.98

+3.9%

Dec 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (16232)	7/13/2003 10:17:30 PM
From: Cacaito	of 17367

Time pass by and I agree with you more. Look, the Fda gave Baxter the right to an "institutional consent" in bleeding subjects with a "blood substitute" that clearly could give hypertension and renal damage (and maybe strokes) to subjects and IT DID, and trial halted forever. Now, Northfield got the same privilege to use "institutional consent" in a "blood substitute" in bleeding subjects that could get "renal damage, hypertension and strokes" as the result of it, cause yes they are different polymerized Hb, but Hb !!! not much different among the Hbs cause they loss the ability to regulate blood vessels the way Rbc do. But, that the meningo trial did not obtain such a privilege is as much xoma failure as is Fda. History, now they are talking "acne", these guys are fresh to the max, or they do not believe bpi works.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next